Immunomedics says milatuzumab shows promise in preclinical studies |
|
|
|
Published
:
Wed, 24 Oct 2007 18:16
|
NEW YORK (Thomson Financial) - Immunomedics Inc. said Wednesday its milatuzumab antibody showed promising therapeutic activity for B-cell lymphoma in animal models in preclinical studies.Milatuzumab is a humanized anti-CD74 antibody being studied for the treatment of multiple myeloma.The San Francisco-based drug maker said the drug showed 'significantly improved efficacy' when combined with anti-CD20 antibodies.The stock fell 1.5% to $2.58.Wanfeng Zhouwz/jwCOPYRIGHTCopyright Thomson Financial News Limited 2007. All rights reserved.The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
BioXell to commence phase IIa trial on Elocalcitol's effects on male infertility 